SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009
TSX symbol: SBS
SemBioSys will hold a special meeting of securityholders at
The management information circular of SemBioSys, as well as the related proxy forms are expected to be mailed to the shareholders of SemBioSys on or about
For the Arrangement to be implemented (a) the Arrangement must be approved at the SemBioSys special meeting by a resolution passed by at least 66 2/3 percent of the votes cast by the securityholders of SemBioSys, and (b) at the Cathedral special meeting of unitholders to be held on the same date as the SemBioSys special meeting, the Arrangement must be approved by a resolution passed by at least 66 2/3 percent of the votes cast by the unitholders of Cathedral.
The Arrangement is also subject to the satisfaction or waiver of certain conditions set forth in the arrangement agreement dated
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, the obtaining of securityholder approvals, any adjustment with respect to the amount of the non-dilutive financing, including the market price of the securities to be received by New SemBioSys, the satisfaction of closing conditions, and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise,
%SEDAR: 00020947EFor further information: SemBioSys Genetics Inc., Abby Garfunkel, Investor Relations, Phone: (403) 717-4185, E-mail: firstname.lastname@example.org; The Trout Group, Christine Labaree, Managing Director, Phone: (617) 583-1307, E-mail: email@example.com; The Equicom Group Inc., Ross Marshall, Vice President, Phone: (416) 815-0700 ext. 238, E-mail: firstname.lastname@example.org